Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Sanson

Showing results (221-230 of 290) with videos related to

Pageof 29
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951Martin J van den Bent, Hendrikus J Dubbink, Marc Sanson, et al.
Annals of Neurology|July 29, 2005
Chromosome 1p loss: a favorable prognostic factor in low-grade gliomasMichèle Kujas, Julie Lejeune, Alexandra Benouaich-Amiel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM TrialThomas Graillon, Marc Sanson, Chantal Campello, et al.
Cell Death Discovery|April 13, 2026
BIRC3/CAV1 co-expression drives GBM aggressiveness as a prognostic signature and therapeutic vulnerabilitySara Franceschi, Mariangela Morelli, Francesca Lessi, et al.
Journal of Neuro-Oncology|December 10, 2014
VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumabAnna Luisa Di Stefano, Marianne Labussiere, Giuseppe Lombardi, et al.
Acta Neuropathologica|December 8, 2023
A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisationLucie Auffret, Yassine Ajlil, Arnault Tauziède-Espariat, et al.
Neuro-Oncology|January 12, 2023
EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selectionDavid Capper, Guido Reifenberger, Pim J French, et al.
Neurology|September 30, 2022
In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of <i>IDH</i>-Mutant Diffuse Gliomas: The <i>IDASPE</i> Prospective StudyAnna Luisa Di Stefano, Lucia Nichelli, Giulia Berzero, et al.
Nature Cancer|March 8, 2021
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilitiesLuciano Garofano, Simona Migliozzi, Young Taek Oh, et al.
Frontiers in Genetics|October 24, 2012
Leveraging ethnic group incidence variation to investigate genetic susceptibility to glioma: a novel candidate SNP approachDaniel I Jacobs, Kyle M Walsh, Margaret Wrensch, et al.
Pageof 29

Showing results (221-230 of 290) with videos related to

Sort By:
Pageof 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951Martin J van den Bent, Hendrikus J Dubbink, Marc Sanson, et al.
Annals of Neurology|July 29, 2005
Chromosome 1p loss: a favorable prognostic factor in low-grade gliomasMichèle Kujas, Julie Lejeune, Alexandra Benouaich-Amiel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM TrialThomas Graillon, Marc Sanson, Chantal Campello, et al.
Cell Death Discovery|April 13, 2026
BIRC3/CAV1 co-expression drives GBM aggressiveness as a prognostic signature and therapeutic vulnerabilitySara Franceschi, Mariangela Morelli, Francesca Lessi, et al.
Journal of Neuro-Oncology|December 10, 2014
VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumabAnna Luisa Di Stefano, Marianne Labussiere, Giuseppe Lombardi, et al.
Acta Neuropathologica|December 8, 2023
A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisationLucie Auffret, Yassine Ajlil, Arnault Tauziède-Espariat, et al.
Neuro-Oncology|January 12, 2023
EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selectionDavid Capper, Guido Reifenberger, Pim J French, et al.
Neurology|September 30, 2022
In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of <i>IDH</i>-Mutant Diffuse Gliomas: The <i>IDASPE</i> Prospective StudyAnna Luisa Di Stefano, Lucia Nichelli, Giulia Berzero, et al.
Nature Cancer|March 8, 2021
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilitiesLuciano Garofano, Simona Migliozzi, Young Taek Oh, et al.
Frontiers in Genetics|October 24, 2012
Leveraging ethnic group incidence variation to investigate genetic susceptibility to glioma: a novel candidate SNP approachDaniel I Jacobs, Kyle M Walsh, Margaret Wrensch, et al.
Pageof 29